BioSig Technologies, Inc.
BSGM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.33 | 0.20 | 0.48 |
| FCF Yield | -2.27% | -5.01% | -12.09% | -3.61% |
| EV / EBITDA | -16.84 | -12.41 | -6.72 | -22.17 |
| Quality | ||||
| ROIC | 974.39% | 1,170.92% | -1,848.47% | -247.32% |
| Gross Margin | 100.00% | 100.00% | 80.07% | 54.88% |
| Cash Conversion Ratio | 0.46 | 0.60 | 0.80 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -48.09% | -65.57% | – | – |
| Free Cash Flow Growth | 72.81% | 20.00% | 18.81% | -0.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.01 | -0.02 | 0.33 |
| Interest Coverage | -1,169.27 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.17 | 0.11 |
| Cash Conversion Cycle | 994.63 | 2,575.28 | 2,163.06 | 3,450.08 |